Site-Specific vs. Stochastic ADC Conjugation: Which Antibody–Drug Conjugate Strategy Is Better?
Nice Insight
Aug 21, 2026PAO-26-PF-21
Key Takeaways
Stochastic conjugation attaches payloads to naturally occurring amino acids on the antibody, producing a heterogeneous mixture of ADC species with varying drug-to-antibody ratios (DARs).
Site-specific conjugation attaches payloads at predetermined locations on the antibody, generating a more uniform ADC population.
Stochastic methods benefit from extensive manufacturing experience and have enabled multiple commercially successful ADCs.
Site-specific approaches can improve control over DAR, pharmacokinetics, stability, and product consistency.
The choice between the two approaches involves balancing platform maturity, manufacturing complexity, product homogeneity, and desired therapeutic characteristics
Why This Comparison Matters Now
Antibody–drug conjugates have become one of the fastest-growing segments of oncology drug development. By combining the targeting specificity of monoclonal antibodies with the potency of cytotoxic payloads, ADCs aim to selectively deliver highly active drugs to tumor cells while minimizing systemic toxicity.
As the field has matured, developers have increasingly recognized that ADC performance depends not only on the antibody, linker, and payload, but also on how the payload is attached to the antibody. The conjugation strategy directly influences critical quality attributes such as drug loading, stability, pharmacokinetics, efficacy, and safety.
Many of the first-generation ADCs relied on stochastic conjugation methods that attach payloads to naturally occurring amino acids such as lysine or cysteine residues. These approaches proved commercially viable and established the foundation of the modern ADC industry. However, they also generate heterogeneous mixtures of ADC molecules with varying drug loads and conjugation sites.
To address these limitations, developers have invested heavily in site-specific conjugation technologies that allow payload attachment at precisely defined locations. Advances in protein engineering, enzymatic conjugation, and non-natural amino acid incorporation have enabled the production of increasingly homogeneous ADCs with tightly controlled drug loading profiles.
As ADC pipelines continue to expand and payload technologies become more sophisticated, the choice between stochastic and site-specific conjugation has become one of the most important platform decisions in ADC development.
Mechanistic Differences
